A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

Key Who May Qualify: - 18 years of age or older - Diagnosed with one of the following at least 3 months prior to screening: schizophrenia or schizoaffective disorder, bipolar disorder, or major depressive disorder - Diagnosed with at least mild neuroleptic-induced TD for at least 3 months prior to screening Key Who Should NOT Join This Trial: - Have comorbid Parkinsonism or abnormal involuntary movement(s) that is more prominent than TD - Diagnosis of moderate or severe substance use disorder in the last 6 months - History of long QT syndrome, cardiac arrythmia, or severe hepatic impairment Always talk to your doctor about whether this trial is right for you.